The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk ( NVO) does these days. With a bull market coinciding with a ...

Novo Nordisk, a world-leading biopharmaceutical company, demonstrated its full industry chain layout in China, under the theme of "Driving change for generations, Healthy China", at the 2nd China ...

Novo Nordisk A/S is cutting back on recruiting in Denmark after reaching the limits of its home country’s labor market in the ...

Novo Nordisk is encouraged by White House proposals that could support patients using weight-loss drugs, but cautioned that ...

Here are some of the major companies whose stocks moved on the week’s news.

Canada's health regulator has approved Novo Nordisk's weight loss drug Wegovy to reduce the risk of nonfatal heart attack or ...

Novo Nordisk will report the topline results from the REDEFINE-1 trial of CagriSema in obese patients before the end of the ...

The world’s largest philanthropic fund that ultimately controls Novo Nordisk A/S will ramp up its investments outside of ...

Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong ...

According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...

Novo Nordisk stock has been pretty volatile lately, making it hard to judge whether now is a good opportunity to buy shares.